In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sepracor and UCB sign deal for Zyrtec

Executive Summary

Using its successful strategy of developing and patenting improved chemical entities of profitable existing drugs, Sepracor has licensed to UCB Farchim SA exclusive rights (except in the US and Japan) to levocetirizine, an isomer of UCB's Zyrtec (racemic cetirizine), a popular antihistamine.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Chiral Chemistry
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies